Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Neuronetics, Inc.NASDAQ: STIM
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $23.79M fell 5.4% year over year, behind the +14.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Selling, general & admin amounted to 65.1% of revenue in FY2025, down 36.3 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $161.83M (+66.6%) for the fiscal year ending Dec 2026, a step up from the +27.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $23.79M-5.2% QoQ
- Last fiscal yearDec 2025
- $97.16M+27.9% YoY
- LTMMar 2026
- $95.81M+14.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 97.16M USD
- Year-over-year change
- +27.9%
- 4-year CAGR
- +11.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.16M | +27.9% |
| FY2024 | 2024-12-31 | 75.95M | +4.4% |
| FY2023 | 2023-12-31 | 72.74M | -3.6% |
| FY2022 | 2022-12-31 | 75.5M | +19.3% |
| FY2021 | 2021-12-31 | 63.3M | — |
Selling, General & Admin vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.8% is the 4th highest of 10, against a peer median of -2.4%.
- Selling, general & admin amounts to 63.2% of revenue for STIM, versus a peer median of 91.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $95.81M USD | +14.8% | +8.8% | 63.2% | |
| LTM Mar 2026 | $95.47M USD | +58.4% | +7.6% | 83.9% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $91.29M USD | +42.6% | +29.3% | 20.9% |
| LTM Mar 2026 | $74.99M USD | -2.4% | -14.3% | 66.4% | |
| LTM Mar 2026 | €51.66M EUR | +54.2% | +35.0% | 316.6% | |
| LTM Mar 2026 | $43.75M USD | -19.9% | -3.4% | 56.0% | |
| LTM Mar 2026 | $31.65M USD | -26.4% | -17.7% | 91.6% | |
| LTM Mar 2026 | $30.61M USD | -29.9% | +22.1% | 162.2% | |
| LTM Mar 2026 | $29.38M USD | +2.8% | +28.6% | 4753.4% | |
| LTM Mar 2026 | $26.47M USD | -12.7% | +5.5% | 91.6% | |
| Peer median (excluding STIM) | — | -2.4% | +7.6% | 91.6% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M |
| Cost of Revenue | 11.65M | 15.48M | 19.64M | 20.73M | 76.85M |
| Gross Profit | 43.66M | 49.72M | 51.71M | 54.16M | 72.31M |
| Gross Margin | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Research & Development | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M |
| Selling, General & Admin | 63.3M | 75.5M | 72.74M | 75.95M | 97.16M |
| Operating Expenses | 71.22M | 84.83M | 82.26M | 88.72M | 103.74M |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| EBITDA | (26.81M) | (31.96M) | (22.76M) | (34.37M) | (27.12M) |
| EBITDA Margin | -48.5% | -49.0% | -31.9% | -45.9% | -18.2% |
| Operating Income | (27.56M) | (35.11M) | (30.55M) | (34.56M) | (31.44M) |
| Operating Margin | -49.8% | -53.8% | -42.8% | -46.2% | -21.1% |
| Interest Income | 0 | 0 | 24K | 0 | 0 |
| Interest Expense | 3.3M | 3.6M | 5.42M | 7.29M | 8.42M |
| Other Income / Expenses | (3.61M) | (2.1M) | 365K | (9.18M) | (7.56M) |
| Income Before Tax | (31.17M) | (37.21M) | (30.19M) | (43.74M) | (39M) |
| Pre-Tax Margin | -56.4% | -57.1% | -42.3% | -58.4% | -26.1% |
| Income Tax Expense | 0 | 0 | (24K) | (14K) | 0 |
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.71M) | (39M) |
| Net Margin | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% |
| EPS (Basic) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| EPS (Diluted) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| Weighted Avg Shares | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
| Weighted Avg Shares (Diluted) | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.